In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
Note: Muscle weakness affects the quality of life in people with acromegaly. Doctora Elena Valassi takes a fascinating look at what happens to muscles when exposed to excess Growth Hormone. Her work is of paramount
Podcast and Survey: Clinical features of acromegaly. In this podcast, Dr. Blevins dives into those clinical features of Acromegaly with a fascinating discussion about symptoms and signs and gives us an unfettered glimpse into the
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
We caught up with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic in Phoenix, Arizona, and Dr. Lewis Blevins Medical Director of the California Center for Pituitary Disorders at
Your insights matter. From J D Faccinetti – co-founder and chief editor – In the awareness business coming up with new, fresh, creative ideas is essential to get your message across, particularly these days when breaking
Dr. Alan Krasner, Chief Medical Officer, and Dr. Chris Cook, Medical Director, Endocrinology at Crinetics Pharmaceuticals offer an in-depth look at clinical studies. In this podcast, we cover a promising molecule – CRNOO808 – under
A few weeks ago, Dan Jeffreys, a UK based author, musician, and patient advocate sent me a message to tell me about his latest project. He told me he started AcroTales to encourage people to share their
As we reported a few months back, the Canadian International Acromegaly conference offered exciting presentations and discussions. If you have acromegaly, have a family member that suffers from the disease, or you are a healthcare
The third podcast in our series on drug development touches on the effort that industry is making to partner with patients to understand needs, preferences, and attitudes, and to develop insights that would result in
This is the first in a series of 6 podcasts on the ins and outs of drug development. In it, we discuss the journey that a promising molecule takes to develop into a life-saving medication and
We are thrilled to announce that Acromegaly will be the focus of a PFDD (Patient-Focused Drug Development) meeting sponsored by Acromegaly Community Inc., a patient support organization based in the US. The meeting will take
From the desk of Jorge D Faccinetti, co-founder – The Spanish Society of Endocrinology or SEEN (Sociedad Española de Endocrinologia y Nutricion) had their annual conference – Congreso, in Spanish – this past October in Bilbao,